3 completed, 2 active not recruiting, 1 recruiting. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Active not recruiting 2, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
Follow Multiple Sclerosis, Primary Progressive: new trials by email Literature Review of Multiple Sclerosis, Primary Progressive trials Research Report on Multiple Sclerosis, Primary Progressive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis KYV-101, Standard lymphodepletion regimen, Anti-CD20 mAB - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Active not recruiting | Kyverna Therapeutics | 120 | 2024-09-20 | 2025-01-13 |
| Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy Clemastine Fumarate, Placebo - Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing-Remitting | Phase 1 / Phase 2 | Recruiting | University of California, San Francisco | 74 | 2023-08-01 | 2026-07-02 |
| Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis N-acetyl cysteine, Placebo - Multiple Sclerosis, Multiple Sclerosis, Primary Progressive | Phase 2 | Active not recruiting | Emmanuelle Waubant, MD PhD | 98 | 2022-02-16 | 2026-03-11 |
| Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Insulin, Placebo (Sterile diluent) - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 105 | 2017-12-01 | 2023-03-10 |
| Hydroxychloroquine in Primary Progressive Multiple Sclerosis Hydroxychloroquine - Multiple Sclerosis, Primary Progressive | Phase 2 | Completed | University of Calgary | 35 | 2016-11-01 | 2021-07-30 |
| Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis ibudilast, Placebo oral capsule - Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive | Phase 2 | Completed | MediciNova | 255 | 2013-11-01 | 2020-07-28 |
Multiple Sclerosis, Chronic Progressive (6) · Multiple Sclerosis (3) · Multiple Sclerosis, Relapsing-Remitting (2) · Autoimmune Diseases (1)
Autoimmune Diseases of the Nervous System (6) · Chronic Disease (6) · Demyelinating Autoimmune Diseases, CNS (6) · Demyelinating Diseases (6) · Disease Attributes (6) · Immune System Diseases (6) · Nervous System Diseases (6) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Autoimmune Diseases (5) · Multiple Sclerosis (3)
Acetylcysteine (1) · Clemastine (1) · Hydroxychloroquine (1) · Insulin (1) · Sugars (1) · ibudilast (1)
Emmanuelle Waubant, MD PhD (1) · Johns Hopkins University (1) · Kyverna Therapeutics (1) · MediciNova (1) · University of Calgary (1) · University of California, San Francisco (1)
United States (5) · Canada (1)
Ari J Green, MD, MCR (1) · Ellen Mowry, MD, MCR (1) · Marcus Koch (1) · Robert J Fox, MD, FAAN (1) · Scott Newsome, DO (1)
PMID 30157388, PMID 33054533, PMID 33410109, PMID 36182028, PMID 36214614, PMID 37537928, PMID 38157653, PMID 39217272, PMID 41342004, PMID 41509523
U01NS082329 (1)